MA45129A - Traitements du cancer - Google Patents

Traitements du cancer

Info

Publication number
MA45129A
MA45129A MA045129A MA45129A MA45129A MA 45129 A MA45129 A MA 45129A MA 045129 A MA045129 A MA 045129A MA 45129 A MA45129 A MA 45129A MA 45129 A MA45129 A MA 45129A
Authority
MA
Morocco
Prior art keywords
cancer treatments
treatments
cancer
Prior art date
Application number
MA045129A
Other languages
English (en)
Inventor
Hugh Griffith
Chris Pepper
Original Assignee
NuCana plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NuCana plc filed Critical NuCana plc
Publication of MA45129A publication Critical patent/MA45129A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA045129A 2016-06-01 2017-05-31 Traitements du cancer MA45129A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1609600.0A GB201609600D0 (en) 2016-06-01 2016-06-01 Cancer treatments

Publications (1)

Publication Number Publication Date
MA45129A true MA45129A (fr) 2021-05-05

Family

ID=56410849

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045129A MA45129A (fr) 2016-06-01 2017-05-31 Traitements du cancer

Country Status (19)

Country Link
US (2) US11400107B2 (fr)
EP (1) EP3463384A1 (fr)
JP (2) JP7367910B2 (fr)
KR (2) KR20190011770A (fr)
CN (1) CN109562119A (fr)
AU (1) AU2017273124B2 (fr)
BR (1) BR112018074981A2 (fr)
CA (1) CA3025442C (fr)
CL (2) CL2018003443A1 (fr)
EA (1) EA038030B1 (fr)
GB (1) GB201609600D0 (fr)
IL (1) IL263123B (fr)
MA (1) MA45129A (fr)
MX (1) MX2018014840A (fr)
MY (1) MY199129A (fr)
PH (1) PH12018502491A1 (fr)
SG (1) SG11201810196RA (fr)
WO (1) WO2017207993A1 (fr)
ZA (1) ZA201807811B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104974206B (zh) 2011-03-01 2019-08-23 努卡那生物医药有限责任公司 用于治疗癌症的5-氟-2’-脱氧尿苷的氨基磷酸酯衍生物
AU2015352203B2 (en) 2014-11-28 2019-08-15 NuCana plc New 2' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compounds
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201609601D0 (en) * 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
EP4323362A1 (fr) 2021-04-16 2024-02-21 Gilead Sciences, Inc. Procédés de préparation de carbanucléosides à l'aide d'amides

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
GB0505781D0 (en) 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
US7888330B2 (en) 2005-11-09 2011-02-15 Wayne State University Phosphoramidate derivatives of FAU
WO2009036099A1 (fr) 2007-09-10 2009-03-19 Boston Biomedical, Inc. Groupe innovant d'inhibiteurs de la voie stat3 et d'inhibiteurs de la voie des cellules souches cancéreuses
CN102144163A (zh) 2008-04-10 2011-08-03 麻省理工学院 关于鉴定和使用靶向癌症干细胞的试剂的方法
WO2012040126A1 (fr) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Analogues de nucléotides substitués
CN104974206B (zh) 2011-03-01 2019-08-23 努卡那生物医药有限责任公司 用于治疗癌症的5-氟-2’-脱氧尿苷的氨基磷酸酯衍生物
JP2017516779A (ja) 2014-05-28 2017-06-22 アイデニクス・ファーマシューティカルズ・エルエルシー 癌治療のためのヌクレオシド誘導体
JP6982957B2 (ja) * 2014-06-25 2021-12-17 ヌカナ ピーエルシー ゲムシタビンプロドラッグ
MX2020004054A (es) * 2014-06-25 2021-11-30 NuCana plc Formulacion que comprende un profarmaco de gemcitabina.
AU2015352203B2 (en) * 2014-11-28 2019-08-15 NuCana plc New 2' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compounds
BR112017024461B1 (pt) * 2015-05-14 2023-04-04 NuCana plc Usos de nuc-1031 para o tratamento de câncer
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201713916D0 (en) 2017-08-30 2017-10-11 Nucana Biomed Ltd Treatment regimens
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis

Also Published As

Publication number Publication date
US11400107B2 (en) 2022-08-02
AU2017273124B2 (en) 2022-09-29
CA3025442A1 (fr) 2017-12-07
EP3463384A1 (fr) 2019-04-10
AU2017273124A1 (en) 2018-12-13
EA201892803A1 (ru) 2019-06-28
IL263123B (en) 2022-09-01
CL2018003443A1 (es) 2019-08-09
ZA201807811B (en) 2024-05-30
SG11201810196RA (en) 2018-12-28
CA3025442C (fr) 2024-02-20
US20190374564A1 (en) 2019-12-12
PH12018502491A1 (en) 2019-09-09
WO2017207993A1 (fr) 2017-12-07
IL263123A (en) 2018-12-31
BR112018074981A2 (pt) 2019-03-12
KR20190011770A (ko) 2019-02-07
CL2021002669A1 (es) 2022-05-27
JP2022051965A (ja) 2022-04-01
EA038030B1 (ru) 2021-06-25
GB201609600D0 (en) 2016-07-13
KR20220142538A (ko) 2022-10-21
CN109562119A (zh) 2019-04-02
MX2018014840A (es) 2019-03-14
US20230218655A1 (en) 2023-07-13
MY199129A (en) 2023-10-17
JP2019521971A (ja) 2019-08-08
JP7367910B2 (ja) 2023-10-24

Similar Documents

Publication Publication Date Title
MA49295A (fr) Traitements du cancer de l'utérus
MA45129A (fr) Traitements du cancer
DK3240801T3 (da) Kombinationstumorimmunterapi
DK3389778T3 (da) Indretning til fotodynamisk behandling
HUE038541T2 (hu) Rák kezelési módszerek
KR20180084772A (ko) 암 치료를 위한 조합 치료법
MA47408A (fr) Traitement du cancer
MA45780A (fr) Méthodes de traitement du cancer de la prostate
DK3393478T3 (da) Kombinationsterapi
FI20165867A (fi) Valoherkiste
DK3462839T4 (da) Energibesparende drivhusafskærmning
DOS2016000090S (es) Cierre
DK3201559T3 (da) Patronhylster
DK3408265T3 (da) Terapeutiske forbindelser
DK3576740T3 (da) Cancerbehandling
DE112017000734A5 (de) Glycolsensor
DK3407909T3 (da) Cancerbehandling
MA45420A (fr) Traitements combinés avec seribantumab
DK3277813T3 (da) Hidtil ukendt terapi
DK3436447T3 (da) Isoquinolinyl-triazolon-komplekser
DK3405212T3 (da) Cancervacciner
KR20180084983A (ko) 암의 치료를 위한 피리미도-피리미다지논의 용도
ITUB20160858A1 (it) Apparato per trattamenti di radiofrequenza
DE112017000296A5 (de) Radgeschwindigkeitssensorvorrichtung
DK3509715T3 (da) Rouletteapparat